Disc Medicine (IRON) is down -6.8%, or -$5.23 to $71.85.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Street sees buying opportunity as Disc Medicine slips on FDA review delay
- Stifel sees weakness in Disc Medicine shares as buying opportunity
- FDA pushes back reviews of several fast-tracked medicines, Reuters reports
- Disc Medicine selloff brings buying opportunity, says Wedbush
- Maintaining a Buy on IRON: Confidence in Bitopertin’s Regulatory Path, Commercial Readiness, and Broader Hematology Pipeline Upside